HPV Vaccine Safety and Immune Response Study
Part of Cancer clinical trials.
This study tests a 9-valent HPV vaccine (protects against 9 types of human papillomavirus) in women who have already completed a previous HPV vaccine series. Researchers will check how safe the new vaccine is and how well your immune system responds to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a female aged 18–45 years old
- You completed a full 3-dose HPV vaccine series (XinKeNing, XiRuiShi, or WoZeHui) at least 12 months before enrolling
- You are willing and able to attend follow-up visits and provide blood samples over several months
- You agree not to become pregnant or will use reliable birth control for 8 months after your first study dose
- You are in general good health with no serious chronic illnesses, immune disorders, or unstable asthma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well two types of domestic HPV vaccines and one imported HPV vaccine boost your immune system. It is for girls aged 13-14 who have already finished their HPV vaccine shots about a month ago.
This trial tests a 9-type HPV vaccine to see how well it works, how it helps the body build protection, and whether it’s safe. It’s for healthy Chinese women who have not had HPV vaccination before and meet specific health and timing requirements.
This trial tests an 11-type HPV vaccine to prevent infection from multiple HPV strains. If you enroll, you’ll receive scheduled vaccine doses and have health and gynecologic check-ins to see how well the vaccine works and is tolerated.
This trial studies whether a quadrivalent HPV vaccine is safe and helps the body build protection (immunity) against HPV. It enrolls healthy Chinese females who are not already treated for HPV-related infection.
This trial tests whether different batches of the HPV 9-valent vaccine work consistently. It's for Chinese women aged 18 to 30 who have not had any HPV vaccine or abnormal cervical screening results.
This study tests a new HPV vaccine (V503, known as Gardasil 9) in Chinese women who either previously received the bivalent HPV vaccine (Cervarix) more than a year ago or never had any HPV vaccine. The goal is to see if this vaccine can effectively prevent HPV-related diseases.
Hear when a new Cervical Cancer Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.